8
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Studies of T Lymphocyte Function and Inhibitory Factors in Minimal Change Nephrotic Syndrome

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Plasma obtained from patients with MCNS in active stage suppressed the <sup>3</sup>H-TdR incorporation of autologous or homologous lymphocytes stimulated with PHA-P and E rosette formation, while plasma from patients in remission did not. The depressed mitogenic response of lymphocytes from patients in the active stage significantly improved when the patient’s plasma was substituted for the plasma from inactive MCNS or healthy persons and fetal calf serum. In the preliminary experiment, it was seen that the inhibitory factors were heat stable at 56°C, unadsorbable to charcoal powder and retained in both the permeable and impermeable fractions of collodion bag.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1979
          1979
          02 December 2008
          : 24
          : 4
          : 179-182
          Affiliations
          Department of Pediatrics, Gunma University School of Medicine, Maebashi, Gunma
          Article
          181712 Nephron 1979;24:179–182
          10.1159/000181712
          315034
          be7bebb6-00b4-46e4-b1f7-9b0bad7f02bb
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 07 December 1978
          Page count
          Pages: 4
          Categories
          Original Paper

          Cardiovascular Medicine,Nephrology
          EAC-RFC,Plasma inhibitory factor, 3H-thymidine incorporation,E-RFC,Nephrotic syndrome

          Comments

          Comment on this article